News Quantified

HEPA – hepion pharmaceuticals, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Model Medicines Appoints Dr. Launa Aspeslet as Senior Scientific & Clinical Advisor [Yahoo! Finance]

Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH' Trial [Yahoo! Finance]

Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial

-1.3%

MISS

Form 10-K/A Hepion Pharmaceuticals, For: Dec 31

Form 10-Q Hepion Pharmaceuticals, For: Mar 31

Form NT 10-Q Hepion Pharmaceuticals, For: Mar 31

Form 10-K Hepion Pharmaceuticals, For: Dec 31

Form NT 10-K Hepion Pharmaceuticals, For: Dec 31

Top News Gainers

10/16 Hepion Pharmaceuticals Announces Publication of Data Highlighting CRV431's Potential as a Treatment for Chronic Liver Diseases 43.2%

11/20 Hepion Pharmaceuticals' CRV431 Prevents Cirrhosis in Experimental Model of Severe Liver Disease 38.4%

1/28 Hepion’s NASH Drug Candidate, CRV431, Demonstrates Superior Antifibrotic Efficacy in Expanded Human Liver Study 15.3%

4/23 ContraVir Pharmaceuticals Inc (NYSE: HEPA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 12.7%

11/26 Hepion Pharmaceuticals And Neoleukin Therapeutics: 2 Micro-Cap Pharmaceutical Stocks Priced For 'Non Success' With Promising Drugs [Seeking Alpha] 12.1%

4/30 ContraVir Pharmaceuticals Inc (NYSE: HEPA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $1.75 price target on the stock. 12.0%

3/27 Form 424B5 Hepion Pharmaceuticals, 8.8%

11/7 Hepion Pharmaceuticals to Present at The Liver Meeting(R) 2019 8.3%

12/3 Hepion Pharmaceuticals to Present at the First Annual BioTuesdays Pre-JPM Virtual Conference 8.1%

1/6 Hepion Pharmaceuticals Announces Publication in Expert Opinion on Investigational Drugs 7.4%

Top News Decliners

3/12 Form 8-K Hepion Pharmaceuticals, For: Mar 12 -25.1%

7/29 Hepion Pharmaceuticals Receives FDA Authorization to Proceed with IND Opening Study of CRV431 for NASH -20.6%

8/14 Hepion Pharmaceuticals Announces Dosing of First HBV Patient in 28-Day Study of CRV431 -13.4%

11/21 Hepion Pharmaceuticals' stock rockets after upbeat results of preclinical study of liver cirrhosis treatment [MarketWatch] -11.5%

11/9 ContraVir Pharmaceuticals Inc (NYSE: HEPA) had its "buy" rating re-affirmed by analysts at Roth Capital. -7.3%

1/6 Form 8-K Hepion Pharmaceuticals, For: Jan 06 -6.0%

4/17 Form 8-K Hepion Pharmaceuticals, For: Apr 13 -6.0%

12/10 Hepion Pharmaceuticals Successfully Advances to Next Dosing Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431 -5.9%

2/12 Form 8-K Hepion Pharmaceuticals, For: Feb 12 -5.5%

2/20 Form 8-K Hepion Pharmaceuticals, For: Feb 19 -5.4%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day